Form 4: Xeris Biopharma Holdings Executive Reports Stock Disposal to Cover Tax Obligations
SEC Form 4 Filing
Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.
Summary
- On January 3, 2025, Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, disposed of 12,401 shares of common stock to satisfy income tax obligations.
- The shares were withheld by the issuer in connection with the net settlement of Restricted Stock Units that vested on the same date.
- The transaction was executed at a price of $3.61 per share.
- Following the transaction, Johnson beneficially owns 361,764 shares of Xeris Biopharma Holdings, Inc.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive sold shares to cover tax obligations, which is a common practice.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency of trading activity by corporate insiders.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | Reporting person acquired 1,129 shares under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended. |
| January 3, 2025 | Shares withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested. |
| January 7, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.